News

Call for proposals from EASME-LIFE for NGO's on the European Green Deal

Published on | 5 years ago

Programmes Climate/Environment Green Deal

“EASME" published the LIFE 2020 Call for Proposals from NGOs on the European Green Deal (NGO4GD).

The deadline for applying is Wednesday 31 March 2021 @ 17:00 (Brussels’ time).

A proposal must be submitted by a single non-profit making non-governmental organisation that is primarily active in the areas of environment and/or climate action and established in an EU member state.

There is a total indicative budget of 12 Mio EUR available. The maximum co-financing rate from LIFE 2020 NGO4GD is 60% of the total eligible project costs.

A virtual information session will be held on Tuesday 12 January 2021 from 10:00 to 12:45.

Organisations that meet the above mentioned eligibility criteria are invited to attend.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1784 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.